The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Mitsubishi Chemical to Fix “Overextension” of Pharma Biz, Focus on 4 Therapeutic Areas, Japan/US: CEO
Mitsubishi Chemical Group is set to restructure its pharmaceutical business by retreating from an “overextension” in non-core fields and zeroing in on four therapeutic areas and two markets, Japan and the US, President and CEO Jean-Marc Gilson says. Speaking at…
To read the full story
Related Article
- Mitsubishi Chemical Scraps Regenerative Medicine Unit
February 28, 2024
- CEO Bids Farewell to Mitsubishi Chemical after Group Revamp
February 7, 2024
- Mitsubishi Chemical Scraps Muse Cell Therapy Program
February 15, 2023
- Mitsubishi Tanabe Incurs 33 Billion Yen Operating Loss on Medicago Shutdown
February 8, 2023
BUSINESS
- KalVista Eyes Japan Debut with World’s 1st Oral On-Demand HAE Drug
March 14, 2025
- FDA Rejects Seikagaku’s Herniated Disk Drug
March 14, 2025
- Glaucoma Eye Drop Rocklatan Now Available in Singapore: Santen
March 14, 2025
- Pfizer Japan Files NDA for Tucatinib for HER2 Breast Cancer
March 14, 2025
- Mitsubishi Tanabe’s Oral Edaravone Filed in South Korea
March 14, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…